<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962830</url>
  </required_header>
  <id_info>
    <org_study_id>2014_19</org_study_id>
    <secondary_id>2015-001721-16</secondary_id>
    <nct_id>NCT02962830</nct_id>
  </id_info>
  <brief_title>Sufentanil Pharmacokinetics After Intra Amniotic Injection</brief_title>
  <acronym>2IAS</acronym>
  <official_title>Assessment of Fetal and Maternal Sufentanil Pharmacokinetics After Intra-amniotic Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The fetus may be exposed during pregnancy to nociceptive stimuli because of fetal pathology
      (e.g., malformation) or a diagnostic or therapeutic procedure.

      To date, there is very little data and no consensus on fetal analgesia. The aim of the
      investigators study is to evaluate the pharmacokinetics of Sufentanil after intra amniotic
      injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fetal plasma concentrations</measure>
    <time_frame>at 30 minutes after intra-amniotic injection</time_frame>
    <description>fetal plasma concentrations of morphine derivatives by Ultrahigh Pressure Liquid Chromatography (UPLC) with mass spectometry (Triple Quadrupole Detector)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal plasma concentrations</measure>
    <time_frame>at 30 minutes and at 1, 2, 4, 8, 24 hours after intra-amniotic injection</time_frame>
    <description>Maternal plasma concentrations of morphine derivatives by Ultrahigh Pressure Liquid Chromatography (UPLC) with mass spectometry (Triple Quadrupole Detector)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amniotic fluid concentrations</measure>
    <time_frame>Immediately within 5 min after intra-amniotic injection</time_frame>
    <description>The amniotic fluid concentrations of morphine derivatives by Ultrahigh Pressure Liquid Chromatography (UPLC) with mass spectometry (Triple Quadrupole Detector)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Prenatal Diagnosis</condition>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>intra-amniotic injection of 50 micrograms of Sufentanil</description>
    <arm_group_label>Sufentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Termination of pregnancy for fetal malformation

          -  Gestational age &gt; 24 weeks of gestation

        Exclusion Criteria:

          -  Multiple pregnancy

          -  Allergy or contraindication to sufentanil

          -  Morphinic addiction

          -  fetal gastroschisis, omphalocele or swallowing disorder

          -  maternal cardiac or respiratory distress
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique HOUFFLIN-DEBARGE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Véronique HOUFFLIN-DEBARGE, MD,PhD</last_name>
    <phone>+33-3 20 44 69 08</phone>
    <phone_ext>+33</phone_ext>
    <email>veronique.debarge@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique HOUFFLIN-DEBARGE, MD,PhD</last_name>
    <email>veronique.debarge@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandres, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Véronique Houfflin-Debarge, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fetal pain</keyword>
  <keyword>fetal analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

